Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Price Target from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $37.56.

Several research analysts recently weighed in on VRDN shares. Royal Bank of Canada decreased their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. JMP Securities cut their price target on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently modified their holdings of VRDN. Barclays PLC grew its holdings in shares of Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after purchasing an additional 66,550 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Viridian Therapeutics by 13.1% during the 4th quarter. Rhumbline Advisers now owns 99,938 shares of the company’s stock worth $1,916,000 after purchasing an additional 11,594 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Viridian Therapeutics by 3.3% during the 4th quarter. Principal Financial Group Inc. now owns 178,444 shares of the company’s stock worth $3,421,000 after purchasing an additional 5,634 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Viridian Therapeutics during the 4th quarter worth approximately $1,023,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Viridian Therapeutics by 15.0% during the 4th quarter. Bank of New York Mellon Corp now owns 196,522 shares of the company’s stock worth $3,767,000 after purchasing an additional 25,692 shares in the last quarter.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $15.94 on Thursday. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -3.70 and a beta of 0.41. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a one year low of $9.90 and a one year high of $27.20. The stock’s fifty day moving average is $13.51 and its 200-day moving average is $15.97.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.